P40763

※ Protein Information

Tag	Content
UniProt Accession	STAT3_HUMAN; P40763;
Entrez ID	6774
GenBank Protein ID	NM_003150.3; NM_139276.2; NM_213662.1; XM_005257616.3; XM_005257617.3; XM_011525145.2; XM_011525146.2; XM_017024972.1; XM_017024975.1;
GenBank Nucleotide ID	NP_003141.2; NP_644805.1; NP_998827.1; XP_005257673.2; XP_005257674.2; XP_011523447.1; XP_011523448.1; XP_016880461.1; XP_016880464.1;
Protein Name	Signal transducer and activator of transcription 3 (Acute-phase response factor)
Gene Name	STAT3; APRF
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:17344214, PubMed:18242580, PubMed:23084476). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:17344214). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:12873986). Binds to the interleukin-6 (IL-6)-responsive elements identified in the promo(view all) Functional Description Signal transducer and transcription activator that mediates cellular responses to interleukins, KITLG/SCF, LEP and other growth factors (PubMed:10688651, PubMed:12359225, PubMed:12873986, PubMed:15194700, PubMed:17344214, PubMed:18242580, PubMed:23084476). Once activated, recruits coactivators, such as NCOA1 or MED1, to the promoter region of the target gene (PubMed:17344214). May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4 (PubMed:12873986). Binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes (PubMed:12359225). Activated by IL31 through IL31RA (PubMed:15194700). Acts as a regulator of inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17 or regulatory T-cells (Treg): deacetylation and oxidation of lysine residues by LOXL3, leads to disrupt STAT3 dimerization and inhibit its transcription activity (PubMed:28065600). Involved in cell cycle regulation by inducing the expression of key genes for the progression from G1 to S phase, such as CCND1 (PubMed:17344214). Mediates the effects of LEP on melanocortin production, body energy homeostasis and lactation (By similarity). May play an apoptotic role by transctivating BIRC5 expression under LEP activation (PubMed:18242580). Cytoplasmic STAT3 represses macroautophagy by inhibiting EIF2AK2/PKR activity (PubMed:23084476). Plays a crucial role in basal beta cell functions, such as regulation of insulin secretion (By similarity).
Sequence (Fasta)	MAQWNQLQQL DTRYLEQLHQ LYSDSFPMEL RQFLAPWIES QDWAYAASKE SHATLVFHNL 60 LGEIDQQYSR FLQESNVLYQ HNLRRIKQFL QSRYLEKPME IARIVARCLW EESRLLQTAA 120 TAAQQGGQAN HPTAAVVTEK QQMLEQHLQD VRKRVQDLEQ KMKVVENLQD DFDFNYKTLK 180 SQGDMQDLNG NNQSVTRQKM QQLEQMLTAL DQMRRSIVSE LAGLLSAMEY VQKTLTDEEL 240 ADWKRRQQIA CIGGPPNICL DRLENWITSL AESQLQTRQQ IKKLEELQQK VSYKGDPIVQ 300 HRPMLEERIV ELFRNLMKSA FVVERQPCMP MHPDRPLVIK TGVQFTTKVR LLVKFPELNY 360 QLKIKVCIDK DSGDVAALRG SRKFNILGTN TKVMNMEESN NGSLSAEFKH LTLREQRCGN 420 GGRANCDASL IVTEELHLIT FETEVYHQGL KIDLETHSLP VVVISNICQM PNAWASILWY 480 NMLTNNPKNV NFFTKPPIGT WDQVAEVLSW QFSSTTKRGL SIEQLTTLAE KLLGPGVNYS 540 GCQITWAKFC KENMAGKGFS FWVWLDNIID LVKKYILALW NEGYIMGFIS KERERAILST 600 KPPGTFLLRF SESSKEGGVT FTWVEKDISG KTQIQSVEPY TKQQLNNMSF AEIIMGYKIM 660 DATNILVSPL VYLYPDIPKE EAFGKYCRPE SQEHPEADPG SAAPYLKTKF ICVTPTTCSN 720 TIDLPMSPRT LDSLMQFGNN GEGAEPSAGG QFESLTFDME LTSECATSPM 771 Fasta Sequence >P40763\|STAT3; APRF\|Homo sapiens (Human) MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMELTSECATSPM

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Phosphorylation	Colon cancer/carcinoma	tumor tissue	P		23335526
1	[Reference]: Expression of pSTAT3 in human colorectal carcinoma: correlation with clinico-pathological parameters
2	Phosphorylation	Liver cancer	tumor tissue	P		23460367
2	[Reference]: Furthermore, our data indicated that the increased number and signal transducers and activator of transcription 3 (STAT3) phosphorylation status of infiltrated inflammatory cells was accompanied by increased IL-6 and TNF- mRNA levels in tumor and normal liver tissue in the p27(-/-) mice
3	Phosphorylation	Pancreatic cancer/carcinoma/adenocarcinoma		P		24132924
3	[Reference]: Highly expressed HAb18G/CD147 promoted cellular and clonogenic growth in vitro and tumorigenicity in vivo. Cyclophilin A (CyPA), a ligand of CD147, stimulated STAT3 phosphorylation and its downstream genes cyclin D1/survivin through HAb18G/CD147-dependent mechanisms. HAb18G/CD147 was associated and colocalized with cancer stem cell marker CD44s in lipid rafts. The inhibitors of STAT3 and survivin, as well as CD44s neutralizing antibodies suppressed the HAb18G/CD147-induced cell growth. High HAb18G/CD147 expression in pancreatic cancer was significantly correlated with the poor tumor differentiation, and the high coexpression of HAb18G/CD147-CD44s-STAT3 associated with poor survival of patients with pancreatic cancer.
4	Phosphorylation	Skin cancer		P		24460316
4	[Reference]: It was found that phosphorylated Stat3 level was much higher in skin cancer cells with higher ATF3 expression
5	Phosphorylation	Ovarian cancer/carcinoma		P		15010843
5	[Reference]: Meanwhile, cisplatin also inhibited Stat3 tyrosine phosphorylation and down-regulated BcL-XL anti-apoptotic protein in the cancer cells tested.
6	Phosphorylation	Sarcoma		P		15010843
6	[Reference]: Meanwhile, cisplatin also inhibited Stat3 tyrosine phosphorylation and down-regulated BcL-XL anti-apoptotic protein in the cancer cells tested.
7	Phosphorylation	Endometrial cancer/carcinoma		P		24321270
7	[Reference]: Our immunoblotting assays revealed that TrkB overexpression in IshikawaTrkB cells noticeably increased the phosphorylation of JAK2 and STAT3, which, however, was aborted by TrkB knockdown in HEC-1BshTrkB cells
8	Phosphorylation	Colitis		P		11181699
8	[Reference]: These data suggest that the levels of STAT3 phosphorylation were well correlated to the severity of colitis
9	Phosphorylation	Ulcerative colitis		U		11181699
9	[Reference]: Among STAT family members, STAT3 was most strongly tyrosine phosphorylated in human ulcerative colitis and Crohn's disease patients as well as in dextran sulfate sodium (DSS)-induced colitis in mice.
10	Phosphorylation	Crohn's disease		U		11181699
10	[Reference]: Among STAT family members, STAT3 was most strongly tyrosine phosphorylated in human ulcerative colitis and Crohn's disease patients as well as in dextran sulfate sodium (DSS)-induced colitis in mice.
11	Phosphorylation	Precancerous lesion of gastric cancer	tumor tissue	U		23596790
11	[Reference]: compared with the blank group,the expression levels of STAT3 and p-STAT3 increased in the model group (P < 0.05)
12	Phosphorylation	Neuroblastoma		U		15715521
12	[Reference]: Differentiated human neuroblastoma (SH-SY5Y) cells express endogenous ObR and IR, and respond to leptin and insulin with stimulation of STAT-3 and MAPK (mitogen-activated protein kinase) phosphorylation, and PI3K activity.
13	Phosphorylation	Breast cancer/tumor/carcinoma		U		10853013
13	[Reference]: Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells.
14	Phosphorylation	Prostate cancer/carcinoma/adenocarcinoma		U		10853013
14	[Reference]: Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells.
15	Phosphorylation	Gastric cancer		U		24116074
15	[Reference]: In addition, the expression of IL-6, survivin, STAT3, p-STAT3, and VEGF were increased in human gastric cancer tissues as compared to adjacent normal mucosa
16	Phosphorylation	Bladder cancer		U		15034568; 23526079
16	[Reference]: Overexpression of CDC91L1 also resulted in upregulation of the urokinase receptor (uPAR), a GPI-anchored protein, and in turn increased STAT-3 phosphorylation in bladder cancer cells.
17	Phosphorylation	Small cell lung cancer/carcinoma	tumor tissue	U		22938476
17	[Reference]: The expression levels of STAT3, P-STAT3, and VEGF-C were higher in SCLC than in normal tissue
18	Phosphorylation	Chronic myelogenous leukemia/Chronic myeloid leukemia		C		23872306
18	[Reference]: Functional in vitro assays indicated that the STAT3Y640F mutation leads to a constitutive phosphorylation of the protein
19	Phosphorylation	Glioblastoma		C		24135280
19	[Reference]: Higher levels of p-STAT3 and p-STAT5 were also observed in xenografted tumors from LN-229:EGFR/EGFRvIII cells, as compared with parent, EGFR, or EGFRvIII tumors
20	Lysine Methylation	Glioblastoma		P	K180	23684459
20	[Reference]: Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells
21	Tyrosine Phosphorylation	Malignant gliomas		A	Y705	23740516
21	[Reference]: The phosphorylation of STAT3 Tyr705, but not Ser727, was inhibited by CTS, and STAT3 nuclear translocation was attenuated
22	Tyrosine Phosphorylation	Bladder cancer		N	Y705	18939995
22	[Reference]: We targeted the Stat3 signaling pathway in bladder cancer cells using an adenovirus-mediated dominant-negative Stat3 (Y705F) and a small molecule compound, STA-21. Both prohibited cell growth and induction of apoptosis in these bladder cancer cell lines but not in normal bladder smooth muscle cell (BdSMC).
23	Tyrosine Phosphorylation	Esophageal squamous cell carcinoma	cell line	P	Y705	23676499
23	[Reference]: AGK levels significantly correlated with increased STAT3 phosphorylation, poorer disease-free survival, and shorter overall survival in primary ESCC
24	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma	tumor tissue	P	Y705	23350355; 24707243; 22374428; 23446809
24	[Reference]: In breast cancer cell lines and xenograft models activated STAT3 participates in breast tumorigenesis, while studies in humans have demonstrated that phosphorylated (tyrosine705)-STAT3 is a marker of good prognosis in breast cancer
25	Tyrosine Phosphorylation	Cancers	cell line	P	Y705	23145121
25	[Reference]: Luteolin promoted the degradation of Tyr(705)- and Ser(727)-phosphorylated STAT3 through interacting with Hsp90 and induced apoptosis of cancer cells
26	S-Nitrosylation	Inflammatory disease		P	T705	24063605
26	[Reference]: Our results indicate the regulation of STAT3 by NO-based?post-translational?modification?(S-nitrosylation)
27	Tyrosine Phosphorylation	Myeloma		P	Y705	22210382
27	[Reference]: PP inhibition of ATP production, STAT3 Tyr705 phosphorylation, and proliferation was absent in mitochondrial DNA-deficient HEL 92.1.7-(0) cells
28	Tyrosine Phosphorylation	Colon cancer/carcinoma		P	Y705	22754353; 21840932
28	[Reference]: sing genetically engineered STAT3 Y705 KI CRC cells, we demonstrate that STAT3 phosphorylation can regulate the efficiency of colorectal tumorigenesis
29	Tyrosine Phosphorylation	Melanoma	cell line	P	Y705	22899991
29	[Reference]: Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines
30	Tyrosine Phosphorylation	Renal cell carcinoma	cell line	P	Y705	22899991
30	[Reference]: Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines
31	Tyrosine Phosphorylation	Renal cancer/carcinoma	cell line	P	Y705	22982675
31	[Reference]: Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
32	Tyrosine Phosphorylation	Hepatocellular carcinoma/Hepatocarcinoma/Hepatoma		P	Y705	21311975
32	[Reference]: XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells
33	Tyrosine Phosphorylation	Pancreatic cancer/carcinoma/adenocarcinoma		U	Y705	18519681
33	[Reference]: Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells.
34	Tyrosine Phosphorylation	Prostate cancer/carcinoma/adenocarcinoma		U	Y705	22307624; 19147545
34	[Reference]: Tyrosine Phosphorylation Is Increased in Clinical Castration-Resistant Prostate Cancer Samples;
35	Tyrosine Phosphorylation	Glioblastoma		U	Y705	20455003
35	[Reference]: Y705 phosphorylation is a prognostic factor for survival (patients with higher levels had shorter overall survival than those with lower levels)
36	Tyrosine Phosphorylation	Fibrosarcoma		U	Y705	21575192
36	[Reference]: Y705 phosphorylation was significantly associated with tumor grade.
37	Tyrosine Phosphorylation	B-cell like diffuse large B cell tumors		C	Y705	23861822
37	[Reference]: Western blot analysis showed that the pSTAT3 level was higher in mutant STAT3M206K transfected cells compared to WT STAT3WT transfected cells, while the pSTAT3 level was similar in both WT STAT3WT and mutant STAT3M206K transfected cells
38	Serine Phosphorylation	Oral squamous epithelial carcinoma		D	S727	23733313
38	[Reference]: Low expression of PTPN12 and high level of phosphorylation of STAT3 correlated with poor prognosis. Overexpression of PTPN12 inhibited proliferation and migration in OSCC cells. PTPN12 was associated with STAT3 and induced STAT3 dephosphorylation
39	Serine Phosphorylation	Pancreatic cancer/carcinoma/adenocarcinoma	cell lines	D	S727	18519681
39	[Reference]: The decrease in STAT3(Tyr705) phosphorylation was linked to a TGFbeta/Smad4-dependent and enhanced activation of extracellular signal-regulated kinases, which caused an increase in serine phosphorylation of STAT3(Ser727)
40	Serine Phosphorylation	Cancers	cell line	P	S727	23145121
40	[Reference]: Luteolin promoted the degradation of Tyr(705)- and Ser(727)-phosphorylated STAT3 through interacting with Hsp90 and induced apoptosis of cancer cells
41	Serine Phosphorylation	Breast cancer/tumor/carcinoma	cell line	P	S727	23329839; 23329648
41	[Reference]: p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth
42	Serine Phosphorylation	Melanoma		P	S727	22418867
42	[Reference]: Ser727 is constitutively phosphorylated in signal transducer and activator of transcription 3 (STAT3) in human melanocytes and melanoma cells
43	Serine Phosphorylation	Prostate cancer/carcinoma/adenocarcinoma		P	S727	23941877
43	[Reference]: The correlation between p-Ser727-STAT3 level and Gleason score (specific scoring system for prostate cancer and provided by Biomax) was analyzed by 2 test. Notably, the significant correlation between p-Ser727-STAT3 level and Gleason score (P = 0.0115, 2 = 11.035; Table 2) was identified
44	Serine Phosphorylation	Thyroid cancer/carcinoma	tumor tissue	U	S727	17209045
44	[Reference]: Ras/ERK1/2-mediated STAT3 Ser727 phosphorylation by familial medullary thyroid carcinoma-associated RET mutants induces full activation of STAT3 and is required for c-fos promoter activation, cell mitogenicity, and transformation.

※ Disease Cross-ref Annotation

Database	Annotation
Cancer Gene Census	T-cell large granular lymphocytic leukaemia paediatric large granular lymphocytic leukaemia
CTD (Curated) (count: 51) (view all)	MESH:D000230 ; Adenocarcinoma MESH:D001169 ; Arthritis, Experimental MESH:D001171 ; Arthritis, Juvenile MESH:D050197 ; Atherosclerosis MESH:D001284 ; Atrophy OMIM:615952 ; AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET, 1 MESH:D001327 ; Autoimmune Diseases MESH:D002545 ; Brain Ischemia MESH:D001943 ; Breast Neoplasms MESH:D002277 ; Carcinoma MESH:D002294 ; Carcinoma, Squamous Cell MESH:C535575 ; Carcinoma, squamous cell of head and neck MESH:D006332 ; Cardiomegaly MESH:D009202 ; Cardiomyopathies MESH:D002471 ; Cell Transformation, Neoplastic MESH:D003093 ; Colitis, Ulcerative MESH:D003110 ; Colonic Neoplasms MESH:C566858 ; Copper-Overload Cirrhosis MESH:D003922 ; Diabetes Mellitus, Type 1 MESH:D004195 ; Disease Models, Animal MESH:D005334 ; Fever MESH:D005355 ; Fibrosis MESH:D006521 ; Hepatitis, Chronic MESH:D065630 ; Hernias, Diaphragmatic, Congenital MESH:C567925 ; Hyper-Ige Recurrent Infection Syndrome, Autosomal Dominant MESH:D020244 ; Infarction, Middle Cerebral Artery MESH:D007249 ; Inflammation MESH:D007589 ; Job Syndrome MESH:D015459 ; Leukemia-Lymphoma, Adult T-Cell MESH:D015470 ; Leukemia, Myeloid, Acute MESH:D008113 ; Liver Neoplasms MESH:D008114 ; Liver Neoplasms, Experimental MESH:D008207 ; Lymphatic Metastasis MESH:D015458 ; Leukemia, T-Cell MESH:D017728 ; Lymphoma, Large-Cell, Anaplastic MESH:D016399 ; Lymphoma, T-Cell MESH:D015674 ; Mammary Neoplasms, Animal MESH:D008325 ; Mammary Neoplasms, Experimental MESH:D008527 ; Medulloblastoma MESH:D008569 ; Memory Disorders MESH:D009362 ; Neoplasm Metastasis MESH:D002289 ; Carcinoma, Non-Small-Cell Lung MESH:D010051 ; Ovarian Neoplasms MESH:D010190 ; Pancreatic Neoplasms MESH:D011230 ; Precancerous Conditions MESH:D015452 ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma MESH:D011471 ; Prostatic Neoplasms MESH:D011565 ; Psoriasis MESH:D015427 ; Reperfusion Injury MESH:D013274 ; Stomach Neoplasms MESH:D002583 ; Uterine Cervical Neoplasms
HGMD (count: 42) (view all)	CD076912; Hyper-IgE syndrome; Small deletions CD075563; Hyper-IgE syndrome; Small deletions CD086675; Hyper-IgE syndrome; Small deletions CG086678; Hyper-IgE syndrome; Gross deletions CM085729; Hyper-IgE syndrome; Missense/nonsense CM086668; Hyper-IgE syndrome; Missense/nonsense CM086673; Hyper-IgE syndrome; Missense/nonsense CM074584; Hyper-IgE syndrome; Missense/nonsense CM074585; Hyper-IgE syndrome; Missense/nonsense CM076545; Hyper-IgE syndrome; Missense/nonsense CM076544; Hyper-IgE syndrome; Missense/nonsense CM076549; Hyper-IgE syndrome; Missense/nonsense CM086679; Hyper-IgE syndrome; Missense/nonsense CM074583; Hyper-IgE syndrome; Missense/nonsense CM083173; Hyper-IgE syndrome; Missense/nonsense CM077976; Hyper-IgE syndrome; Missense/nonsense CM083174; Hyper-IgE syndrome; Missense/nonsense CM083171; Hyper-IgE syndrome; Missense/nonsense CM074586; Hyper-IgE syndrome; Missense/nonsense CM076547; Hyper-IgE syndrome ?; Missense/nonsense CM086669; Hyper-IgE syndrome; Missense/nonsense CM083168; Hyper-IgE syndrome; Missense/nonsense CM092292; Hyper-IgE syndrome; Missense/nonsense CM076543; Hyper-IgE syndrome ?; Missense/nonsense CM086670; Hyper-IgE syndrome; Missense/nonsense CM076550; Hyper-IgE syndrome; Missense/nonsense CM076542; Hyper-IgE syndrome; Missense/nonsense CM086671; Hyper-IgE syndrome; Missense/nonsense CM076546; Hyper-IgE syndrome; Missense/nonsense CM077977; Hyper-IgE syndrome; Missense/nonsense CM086672; Hyper-IgE syndrome; Missense/nonsense CM076541; Hyper-IgE syndrome; Missense/nonsense CM083167; Hyper-IgE syndrome; Missense/nonsense CM083172; Hyper-IgE syndrome; Missense/nonsense CM077975; Hyper-IgE syndrome; Missense/nonsense CM077978; Hyper-IgE syndrome; Missense/nonsense CM076548; Hyper-IgE syndrome; Missense/nonsense CM083169; Hyper-IgE syndrome; Missense/nonsense CM083170; Hyper-IgE syndrome; Missense/nonsense CM086674; Hyper-IgE syndrome; Missense/nonsense CS086677; Hyper-IgE syndrome; Splicing CS086676; Hyper-IgE syndrome; Splicing
GWASdb (count: 24) (view all)	rs3809758; Sudden cardiac arrest; coronary artery disease rs2293152; Multiple sclerosis; multiple sclerosis rs8069645; Multiple complex diseases; Null rs8069645; Crohn's disease; Crohn's disease rs3816769; Multiple complex diseases; Null rs3816769; Urinary metabolites; kidney disease rs6503695; Crohn's disease; Crohn's disease rs9891119; Multiple sclerosis; multiple sclerosis rs9891119; Crohn's disease; Crohn's disease rs744166; Multiple complex diseases; Null rs744166; Crohn's disease; Crohn's disease rs744166; Multiple sclerosis; multiple sclerosis rs744166; Asthma; asthma rs744166; Urinary metabolites; kidney disease rs3785898; Multiple complex diseases; Null rs3785898; Urinary metabolites; kidney disease rs12942547; Inflammatory bowel disease; inflammatory bowel disease rs1026916; Multiple complex diseases; Null rs1026916; Urinary metabolites; kidney disease rs7211777; Multiple complex diseases; Null rs7211777; Urinary metabolites; kidney disease rs7211777; Insulin resistance; type 2 diabetes mellitus rs4796793; Drug response to Interferon Alfacon-1; Null rs4796793; Amyotrophic lateral sclerosis (sporadic); amyotrophic lateral sclerosis

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 27) (view all)	181 FNYKTLKSQGDMQDL dbPAF 194 DLNGNNQSVTRQKMQ dbPAF 196 NGNNQSVTRQKMQQL dbPAF 429 GRANCDASLIVTEEL dbPAF 440 TEELHLITFETEVYH dbPAF 446 ITFETEVYHQGLKID dbPAF 45 IESQDWAYAASKESH dbPAF 539 LLGPGVNYSGCQITW dbPAF 540 LGPGVNYSGCQITWA dbPAF 605 LSTKPPGTFLLRFSE dbPAF 632 EKDISGKTQIQSVEP dbPAF 636 SGKTQIQSVEPYTKQ dbPAF 641 IQSVEPYTKQQLNNM dbPAF 657 FAEIIMGYKIMDATN dbPAF 674 VSPLVYLYPDIPKEE dbPAF 686 KEEAFGKYCRPESQE dbPAF 691 GKYCRPESQEHPEAD dbPAF 701 HPEADPGSAAPYLKT dbPAF 705 DPGSAAPYLKTKFIC dbPAF 708 SAAPYLKTKFICVTP dbPAF 714 KTKFICVTPTTCSNT dbPAF 716 KFICVTPTTCSNTID dbPAF 717 FICVTPTTCSNTIDL dbPAF 719 CVTPTTCSNTIDLPM dbPAF 721 TPTTCSNTIDLPMSP dbPAF 727 NTIDLPMSPRTLDSL dbPAF 79 LQESNVLYQHNLRRI dbPAF
Acetylation (count: 13) (view all)	161 RVQDLEQKMKVVENL PLMD 244 DEELADWKRRQQIAC PLMD 370 KIKVCIDKDSGDVAA PLMD 383 AALRGSRKFNILGTN PLMD 409 GSLSAEFKHLTLREQ PLMD 49 DWAYAASKESHATLV PLMD 548 GCQITWAKFCKENMA PLMD 631 VEKDISGKTQIQSVE PLMD 679 YLYPDIPKEEAFGKY PLMD 685 PKEEAFGKYCRPESQ PLMD 707 GSAAPYLKTKFICVT PLMD 709 AAPYLKTKFICVTPT PLMD 87 QHNLRRIKQFLQSRY PLMD
Ubiquitination (count: 22) (view all)	161 RVQDLEQKMKVVENL PLMD 163 QDLEQKMKVVENLQD PLMD 177 DDFDFNYKTLKSQGD PLMD 180 DFNYKTLKSQGDMQD PLMD 199 NQSVTRQKMQQLEQM PLMD 244 DEELADWKRRQQIAC PLMD 283 QTRQQIKKLEELQQK PLMD 294 LQQKVSYKGDPIVQH PLMD 318 ELFRNLMKSAFVVER PLMD 348 TGVQFTTKVRLLVKF PLMD 383 AALRGSRKFNILGTN PLMD 409 GSLSAEFKHLTLREQ PLMD 574 NIIDLVKKYILALWN PLMD 601 ERAILSTKPPGTFLL PLMD 615 LRFSESSKEGGVTFT PLMD 626 VTFTWVEKDISGKTQ PLMD 631 VEKDISGKTQIQSVE PLMD 642 QSVEPYTKQQLNNMS PLMD 707 GSAAPYLKTKFICVT PLMD 709 AAPYLKTKFICVTPT PLMD 87 QHNLRRIKQFLQSRY PLMD 97 LQSRYLEKPMEIARI PLMD
Malonylation (count: 2)	370 KIKVCIDKDSGDVAA PLMD 383 AALRGSRKFNILGTN PLMD
Methylation (count: 2)	140 TAAVVTEKQQMLEQH PLMD 49 DWAYAASKESHATLV PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

E9PFC7	P40763	HPRD
F5GXF0	P40763	IntAct
F5GYU5	P40763	HPRD
H7C0C9	P40763	MINT
O00570	P40763	IntAct
O14503	P40763	HPRD
O14874	P40763	IntAct
O14920	P40763	IntAct
O15379	P40763	HPRD
O43255	P40763	IntAct
O43283	P40763	IntAct
O43318	P40763	HPRD; IntAct
O43609	P40763	IntAct
O60231	P40763	MINT
O60232	P40763	IntAct
O60674	P40763	HPRD
O60684	P40763	HPRD
O75582	P40763	HPRD
P00533	P40763	HPRD; IntAct
P01589	P40763	HPRD
P02760	P40763	IntAct
P04150	P40763	HPRD
P04439	P40763	IntAct
P04626	P40763	IntAct; MINT
P04632	P40763	IntAct
P05412	P40763	HPRD
P06239	P40763	HPRD
P06454	P40763	HPRD
P07332	P40763	HPRD
P07384	P40763	IntAct
P07900	P40763	HPRD
P07949	P40763	HPRD
P08069	P40763	HPRD
P08238	P40763	HPRD
P08581	P40763	HPRD
P08631	P40763	HPRD
P08887	P40763	HPRD
P09619	P40763	HPRD
P09769	P40763	IntAct
P10275	P40763	HPRD
P10912	P40763	HPRD
P11309	P40763	IntAct
P12931	P40763	HPRD; IntAct
P14784	P40763	HPRD
P15172	P40763	HPRD
P15822	P40763	IntAct
P15927	P40763	HPRD
P15976	P40763	HPRD
P16234	P40763	HPRD
P16591	P40763	HPRD
P16871	P40763	HPRD
P16949	P40763	HPRD
P17181	P40763	HPRD
P17706	P40763	HPRD
P17948	P40763	HPRD
P18031	P40763	MINT
P19525	P40763	HPRD
P19838	P40763	HPRD
P20823	P40763	HPRD
P22455	P40763	HPRD
P22607	P40763	HPRD
P23458	P40763	HPRD
P23769	P40763	HPRD
P24385	P40763	HPRD
P27361	P40763	HPRD
P28482	P40763	HPRD
P29320	P40763	HPRD
P29590	P40763	HPRD
P30101	P40763	HPRD
P30626	P40763	IntAct
P31146	P40763	IntAct
P32246	P40763	HPRD
P32927	P40763	HPRD
P38936	P40763	HPRD
P40189	P40763	HPRD
P40763	P40763	HPRD; IntAct
P40763	P42224	HPRD
P40763	P42229	HPRD
P40763	P42345	HPRD
P40763	P43405	HPRD
P40763	P45983	HPRD
P40763	P45984	IntAct
P40763	P46781	IntAct
P40763	P48357	HPRD
P40763	P48551	HPRD
P40763	P51617	HPRD
P40763	P51681	HPRD
P40763	P51692	HPRD
P40763	P51813	HPRD
P40763	P52272	IntAct
P40763	P52294	HPRD; MINT
P40763	P52333	HPRD
P40763	P52630	IntAct
P40763	P53365	IntAct
P40763	P55268	IntAct
P40763	P61073	HPRD
P40763	P62136	MINT
P40763	P62913	IntAct
P40763	P63000	HPRD
P40763	P63244	HPRD
P40763	P78347	HPRD
P40763	Q04206	HPRD; IntAct
P40763	Q05655	HPRD
P40763	Q06124	HPRD
P40763	Q06520	IntAct
P40763	Q07666	HPRD; IntAct
P40763	Q08050	HPRD
P40763	Q09472	HPRD
P40763	Q13011	IntAct
P40763	Q13287	HPRD; IntAct
P40763	Q13547	HPRD
P40763	Q14192	IntAct
P40763	Q14289	HPRD
P40763	Q14469	HPRD
P40763	Q14765	HPRD
P40763	Q15788	HPRD
P40763	Q16665	HPRD
P40763	Q4LE28	HPRD
P40763	Q5TA89	HPRD
P40763	Q5VWK5	HPRD
P40763	Q6EEV6	HPRD
P40763	Q6IA86	HPRD
P40763	Q7Z7K2	HPRD
P40763	Q8IUQ4	IntAct
P40763	Q8IXJ9	IntAct
P40763	Q8N6P7	IntAct
P40763	Q8N960	IntAct
P40763	Q8NEM7	IntAct
P40763	Q8TAE8	MINT
P40763	Q8TE76	IntAct
P40763	Q8WW38	IntAct
P40763	Q92665	IntAct
P40763	Q92769	HPRD
P40763	Q92993	HPRD
P40763	Q969D9	HPRD
P40763	Q96G01	IntAct
P40763	Q96RT1	IntAct
P40763	Q99062	HPRD
P40763	Q99590	IntAct
P40763	Q9BVP2	IntAct
P40763	Q9BXP5	IntAct
P40763	Q9BYH8	IntAct
P40763	Q9GZT8	IntAct
P40763	Q9NPH3	HPRD
P40763	Q9P0J0	HPRD
P40763	Q9UBE8	HPRD; IntAct
P40763	Q9UER7	HPRD; IntAct
P40763	Q9UGK3	HPRD
P40763	Q9ULD0	IntAct
P40763	Q9UQR1	HPRD
P40763	Q9Y5S9	IntAct
P40763	Q9Y6X2	HPRD; IntAct

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction